Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol

NCT02720224 ↗

Phase 1 Completed 6 enrolled Estetra Quotient Clinical · collab

NaSingle-groupOpen-labelOther

Summary

This study is being conducted to further understand the elimination pathways, metabolite profile and pharmacokinetic (PK) profile of carbon 14 labelled estetrol (\[14C\] estetrol).

Timeline

Start: 2016-02
Primary completion: 2016-03
Completion: 2016-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ESTETROL ANHYDROUS	Other / unclassified	15 mg	Oral

Indications

No indication recorded.